Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis | Zendy

Stephen J. Nicholls | Zendy; E. Murat Tuzcu | Zendy; Danielle M. Brennan | Zendy; JeanClaude Tardif | Zendy; Steven E. Nissen | Zendy

Open Access

Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis

Author(s) -

Stephen J. Nicholls,

E. Murat Tuzcu,

Danielle M. Brennan,

JeanClaude Tardif,

Steven E. Nissen

Publication year - 2008

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.108.790733

Subject(s) - medicine , cholesterylester transfer protein , coronary atherosclerosis , lipoprotein , cardiology , coronary heart disease , high density lipoprotein , cholesterol

Despite favorable effects on high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol, the cholesteryl ester transfer protein inhibitor torcetrapib failed to slow atherosclerosis progression and increased mortality. We investigated the relationship between lipid changes and progression of coronary atherosclerosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research